Compare Ascendis Pharma A/S (ASND) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.38. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ASND | YMAG | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $15.98 |
52-Week Low | $189.74 | $10.76 |
Enterprise Value | $17.04B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
